Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENGOT-OV56 DOVACC maintenance therapy in ovarian cancer
2020-004738-39Phase 2Active
- Sponsor
- Nordic Society of Gynaecological Oncology
- Start
- May 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in ovarian cancer comparing Olaparib maintenance, Olaparib + Imfinzi maintenance and Olaparib + Imfinzi + UV1 maintenance (3 arms). Primary endpoint: Progression-free survival (PFS) arm A vs arm C. Started May 2021; status: active.
02
Drugs
durvalumabolaparibUV1
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2020-004738-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004738-39.